Loading...
OTCM
DSRNY
Market cap5.74bUSD
, Last price  
USD
Name

DiaSorin SpA

Chart & Performance

D1W1MN
No data to show
P/E
—
P/S
—
EPS
2.99
Div Yield, %
—
Shrs. gr., 5y
0.08%
Rev. gr., 5y
11.40%
Revenues
1.19b
+3.20%
165,339,000179,756,000202,324,000244,612,000304,129,000404,547,000440,003,000433,763,000434,849,000443,770,000499,181,000569,312,000637,487,000669,197,000706,319,000881,305,0001,237,654,0001,361,138,0001,148,210,0001,185,000,000
Net income
187m
+16.99%
4,678,00022,294,00025,219,00037,459,00070,047,00090,418,00099,607,00087,396,00083,028,00084,074,000100,420,000112,383,000139,878,000158,128,000175,735,000247,871,000310,968,000240,907,000159,849,000187,000,000
CFO
359m
+15.12%
21,132,00033,976,00030,348,00047,779,00064,219,00095,791,000108,578,000110,582,000107,717,000119,847,000138,449,000165,597,000167,440,000209,879,000232,670,000304,562,000400,664,000389,341,000311,663,000358,782,000
Earnings
May 08, 2025

Profile

DiaSorin S.p.A. develops, manufactures, and distributes immunodiagnostics and molecular diagnostics testing kits in Europe, Africa, North America, Central and South America, the Asia Pacific, and China. The company provides various immunodiagnostic LIAISON platforms, including LIAISON XS, LIAISON XL, and LIAISON XL LAS; and molecular diagnostics platform comprising of LIAISON MDX for use in the amplification of nucleic acids to diagnose viral infections through the identification of virus in patient's biological sample. It has partnership agreements with QIAGEN for diagnostic solution for Latent Tuberculosis detection; TTP for the development of molecular Point-of-Care solution; and MeMed for the launch of a test differentiating between viral and bacterial infections. The company was founded in 1968 and is headquartered in Saluggia, Italy.
URL
https://www.diasorin.com/
IPO date
Jul 19, 2007
Employees
3,278
Domiciled in
IT
Incorporated in
IT

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,185,000
3.20%
1,148,210
-15.64%
1,361,138
9.98%
Cost of revenue
912,000
911,145
964,166
Unusual Expense (Income)
NOPBT
273,000
237,065
396,972
NOPBT Margin
23.04%
20.65%
29.16%
Operating Taxes
55,000
42,708
85,830
Tax Rate
20.15%
18.02%
21.62%
NOPAT
218,000
194,357
311,142
Net income
187,000
16.99%
159,849
-33.65%
240,907
-22.53%
Dividends
(58,967)
(57,052)
Dividend yield
1.13%
0.75%
Proceeds from repurchase of equity
(18,534)
116,142
BB yield
0.36%
-1.53%
Debt
Debt current
109,649
120,020
Long-term debt
1,038,719
1,154,005
1,301,467
Deferred revenue
Other long-term liabilities
262,000
70,752
80,041
Net debt
659,769
884,877
1,179,685
Cash flow
Cash from operating activities
358,782
311,663
389,341
CAPEX
(113,241)
(113,686)
Cash from investing activities
(49,809)
(29,102)
(231,952)
Cash from financing activities
(245,000)
(235,961)
(333,043)
FCF
517,387
237,640
242,352
Balance
Cash
344,327
378,751
413,218
Long term investments
34,623
26
(171,416)
Excess cash
319,700
321,366
173,745
Stockholders' equity
55,948
2,124,597
1,838,102
Invested Capital
2,691,753
2,480,008
2,764,245
ROIC
8.43%
7.41%
11.85%
ROCE
9.94%
7.90%
12.53%
EV
Common stock shares outstanding
55,869
55,746
58,050
Price
99.56
6.78%
93.24
-28.50%
130.40
-22.13%
Market cap
5,562,289
7.01%
5,197,751
-31.33%
7,569,704
-21.50%
EV
6,222,058
6,081,985
8,750,150
EBITDA
273,000
352,091
550,239
EV/EBITDA
22.79
17.27
15.90
Interest
27,555
34,966
Interest/NOPBT
10.09%
8.81%